60 reports of this reaction
2.0% of all BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE reports
#12 most reported adverse reaction
ERYTHEMA is the #12 most commonly reported adverse reaction for BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE, manufactured by Topco Associates LLC. There are 60 FDA adverse event reports linking BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE to ERYTHEMA. This represents approximately 2.0% of all 2,981 adverse event reports for this drug.
Patients taking BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE who experience erythema should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ERYTHEMA is a less commonly reported adverse event for BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE, but still significant enough to appear in the safety profile.
In addition to erythema, the following adverse reactions have been reported for BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE:
The following drugs have also been linked to erythema in FDA adverse event reports:
ERYTHEMA has been reported as an adverse event in 60 FDA reports for BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ERYTHEMA accounts for approximately 2.0% of all adverse event reports for BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE, making it a notable side effect.
If you experience erythema while taking BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.